Children's hospitals gain legislative victory on 340B orphan drugs

Traynor, Kate
January 2011
American Journal of Health-System Pharmacy;1/15/2011, Vol. 68 Issue 2, p100
Academic Journal
The article reports on the passage of the Medicare and Medicaid Extenders Act of 2010, which reinstates the 340B discounts for orphan drugs. It says that the 340B program was made to restrict the cost of outpatient drugs purchased by participating health centers and children's hospitals. It also states that letters are sent to companies by the Safety Net Hospitals for Pharmaceutical Access (SNHPA) and National Rural Health Association (NRHA) to reinstate the discounts on orphan drugs.


Related Articles

  • Time to revisit the orphan drug law. Garattini, Silvio // European Journal of Clinical Pharmacology;Feb2012, Vol. 68 Issue 2, p113 

    The author reflects on an orphan drug law which was approved by the European Parliament to encourage pharmaceutical companies to develop drugs for approximately 7,000 rare diseases awaiting a therapy. The author suggests that while drugs are costly to develop, there is no doubt that...

  • Will crowdfunding and general solicitation spur orphan drug development for biotechs? Loucks, David // Formulary;Oct2013, Vol. 48 Issue 10, p343 

    The article presents information on the efforts of the U.S. Food and Drug Administration (FDA) to enhance orphan drug development. It states that FDA has offered many incentives to biotech firms to motivate them to increase the production of orphan drugs. It also discusses the benefits of equity...

  • Spare a thought for “orphan” drugs. Brooks, Michael // New Statesman;2/27/2015, p18 

    The article looks at orphan drugs, or drugs developed to treat rare diseases. The author lauds policies in Europe and the U.S. to spur the development of orphan drugs by subsidizing research on them but says their high cost can make it difficult to provide them to patients once developed. Topics...

  • PhRMA beats Obama administration again in 340B battle. Schencker, Lisa // Modern Healthcare;10/19/2015 THE BEST PLACES TO WORK IN HEALTHCARE, Vol. 45 Issue  

    The article reports on the decision by a federal judge to reject the policy by the administration of U.S. President Barack Obama to provide rural and cancer hospitals discounts on orphan drugs. The Pharmaceutical Research and Manufacturers of America has filed a lawsuit twice over the Department...

  • Insurance Companies' Perspectives on the Orphan Drug Pipeline. Handfield, Robert; Feldstein, Josh; Kaddis, Atheer A. // American Health & Drug Benefits;Nov/Dec2013, Vol. 6 Issue 9, p589 

    No abstract available.

  • Insurance Companies' Perspectives on the Orphan Drug Pipeline. Handfield, Robert; Feldstein, Josh; Kaddis, Atheer A. // American Health & Drug Benefits;Nov/Dec2013, Vol. 6 Issue 9, p589 

    The article focuses on a study which determined the views of leading commercial payers in the U.S. regarding providing access to and coverage for orphan drugs and assessed whether and to what degree cost-effectiveness analysis is viewed by payers as important to rare disease coverage. Almost 67...

  • Policymaking for Orphan Drugs and Its Challenges. Rhee, Taeho Greg // AMA Journal of Ethics;Aug2015, Vol. 17 Issue 8, p776 

    The article discusses policymaking for drugs and biologics for rare diseases or conditions, also known as orphan drugs, Orphan Drug Act (ODA) successes such as increased diversity of orphan drugs, and issues not addressed by ODA like high medication costs affecting accessibility.

  • Hope for Orphan Drugs in Act.  // Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p8 

    The article discusses the Creating Hope Act of 2011 intended for rare and pediatric orphan diseases in the U.S.

  • No fat, all muscle. Troy, Peggy // Modern Healthcare;6/6/2011, Vol. 41 Issue 23, p22 

    The author comments on a proposal from U.S. President Barack Obama's administration that would eliminate funding for a program that trains future pediatricians and pediatric specialists in the country. According to the author, this proposed budget cut poses a threat to the healthcare of every...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics